Skip to main navigation Skip to search Skip to main content

Impaired Glucose Metabolism, Anti-Diabetes Medications, and Risk of Thyroid Cancer

  • Yevgeniya Kushchayeva*
  • , Sergiy Kushchayev
  • , Kirk Jensen
  • , Rebecca J. Brown
  • *Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

The prevalence of obesity is progressively increasing along with the potential high risk for insulin resistance and development of type 2 diabetes mellitus. Obesity is associated with increased risk of many malignancies, and hyperinsulinemia has been proposed to be a link between obesity and cancer development. The incidence of thyroid cancer is also increasing, making this cancer the most common endocrine malignancy. There is some evidence of associations between obesity, insulin resistance and/or diabetes with thyroid proliferative disorders, including thyroid cancer. However, the etiology of such an association has not been fully elucidated. The goal of the present work is to review the current knowledge on crosstalk between thyroid and glucose metabolic pathways and the effects of obesity, insulin resistance, diabetes, and anti-hyperglycemic medications on the risk of thyroid cancer development.

Original languageEnglish
Article number555
JournalCancers
Volume14
Issue number3
DOIs
StatePublished - 1 Feb 2022

Keywords

  • Anti-diabetic drugs
  • Cancer risk
  • Diabetes mellitus
  • Insulin resistance
  • Thyroid abnormalities

Fingerprint

Dive into the research topics of 'Impaired Glucose Metabolism, Anti-Diabetes Medications, and Risk of Thyroid Cancer'. Together they form a unique fingerprint.

Cite this